{"product_id":"staar-five-forces-analysis","title":"STAAR Surgical Porter's Five Forces Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFrom Overview to Strategy Blueprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eSTAAR Surgical faces moderate supplier power from specialized component providers and strong buyer expectations driven by reimbursement and clinical outcomes, while regulatory hurdles and IP create significant barriers to new entrants. Competitive rivalry and substitute technologies pressure pricing and innovation-led differentiation. This brief snapshot only scratches the surface—unlock the full Porter's Five Forces Analysis to explore STAAR Surgical’s competitive dynamics and strategic implications in detail.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized biomaterials concentration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSTAAR depends on proprietary collamer and optical‑grade polymers from very few qualified suppliers, concentrating supplier power. Limited options (often under five) raise bargaining leverage and switching costs as revalidation commonly takes 6–12 months. Disruptions can depress yields and lengthen lead times by 3–6 months. Long‑term contracts and selective dual‑sourcing mitigate but do not eliminate the risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrecision equipment and sterilization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUltra-precision lathing, polishing and sterilization suppliers are highly specialized and regulated, subject to FDA quality system regulations (21 CFR 820) and ISO 11137 validation requirements, making qualification and process validation slow and costly. This raises switching barriers and lets vendors pass through compliance- and capacity-driven price increases. STAAR’s scale and production planning, however, enable negotiation for priority slots and volume discounts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and quality dependencies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eClass III implantables require PMA-level validated materials and documented change control under FDA 21 CFR 814 and quality system regs 21 CFR 820, giving suppliers leverage since any component change can trigger PMA supplements with FDA review timelines often around 180 days. Suppliers with clean compliance histories command price premiums, while STAAR mitigates risk through strict QA, supplier audits, and joint technical development. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVolume leverage is moderate\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSTAAR reported 2024 revenue of $262.4M; volumes remain smaller than large cataract IOL peers, limiting scale leverage. Suppliers may favor larger medtech customers during component shortages. Multi‑year volume commitments and rising demand in Asia should incrementally strengthen STAAR’s bargaining position.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSmaller scale vs top peers — limits discounting\u003c\/li\u003e\n\u003cli\u003eSupply shortages: higher-priority customers first\u003c\/li\u003e\n\u003cli\u003eMulti-year contracts unlock better pricing\u003c\/li\u003e\n\u003cli\u003eAsia growth could improve leverage over time\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeographic and logistics risks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp supply chains for staar face export controls resin shortages and shipping volatility that drove peak surcharges of up to during disruptions in temperature logistics sterile implants add roughly distribution costs complexity. suppliers can pass through so maintains inventory buffers regional redundancy reduce exposure.\u003e\n\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eResin shortages: supply tightness in 2024\u003c\/li\u003e\n\u003cli\u003eShipping volatility: peak surcharges ~40%\u003c\/li\u003e\n\u003cli\u003eCold chain adds 10–20% cost\u003c\/li\u003e\n\u003cli\u003eMitigation: inventory buffers, regional redundancy\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupplier concentration, 6-12m revalidation; \u003cstrong\u003e$262.4M\u003c\/strong\u003e, peak surcharges ~40%\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSTAAR relies on \u0026lt;5 qualified polymer and ultra‑precision suppliers, raising switching costs (revalidation 6–12 months) and enabling price pass‑through; PMA change controls add ~180‑day FDA review risk. 2024 revenue $262.4M limits scale leverage vs peers; suppliers favored larger customers during 2024 shortages. Peak surcharges hit ~40%; cold‑chain adds 10–20%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e$262.4M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQualified suppliers\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;5\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevalidation\u003c\/td\u003e\n\u003ctd\u003e6–12 months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA review\u003c\/td\u003e\n\u003ctd\u003e~180 days\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePeak surcharges\u003c\/td\u003e\n\u003ctd\u003e~40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCold‑chain cost\u003c\/td\u003e\n\u003ctd\u003e10–20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eTailored Porter's Five Forces analysis for STAAR Surgical revealing competitive intensity, supplier and buyer power, threat of new entrants and substitutes, and disruptive forces shaping pricing, margins, and strategic positioning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, one-sheet Porter's Five Forces for STAAR Surgical that turns complex competitive pressures into instant, slide-ready insights—customize force levels, swap in your own data, and export spider charts without macros for fast boardroom decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSurgeons and ASCs as key buyers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOphthalmic surgeons and ambulatory surgery centers (ASCs) are the primary adopters of ICLs and thus hold strong purchasing influence over STAAR Surgical’s EVO\/Visian ICL offerings.\u003c\/p\u003e\n\u003cp\u003eTheir clinical expertise and case volumes confer negotiation leverage on pricing, training support, and inventory terms, while demonstrated outcomes and ease of use blunt price sensitivity.\u003c\/p\u003e\n\u003cp\u003eKOL advocacy, supported by over 1 million ICLs implanted globally, can shift surgeon preference toward STAAR’s products.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDistributor and hospital procurement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn many markets distributors and hospital groups aggregate demand via group purchasing organizations and tenders, creating significant price pressure and longer payment cycles—often extending to around 90 days. Bundling and tender strategies can compress margins, sometimes causing double-digit price concessions, so STAAR must offer competitive contracts and strong service levels. Exclusive distributor agreements can concentrate purchasing but also stabilize volumes and forecasting.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient pay and reimbursement dynamics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMost refractive ICLs are cash‑pay, with typical 2024 market prices around $4,000–$6,000 per eye versus LASIK\/S MILE $2,000–$3,000, making patients more price sensitive. Perceived value—improved night vision, reversibility, range to treat high myopia—supports premium pricing. Widespread financing and DTC education lower sticker shock and raise conversion. Where reimbursed (limited indications), payer formularies and rules can effectively cap net prices.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSwitching costs and training\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eOnce surgeons are trained and inventories are organized, switching costs rise as customized sizing and integrated preoperative workflows embed STAAR devices into daily practice, progressively reducing buyer power. Over time this clinical and logistical entrenchment creates stickiness, though targeted competitor training programs and financial incentives can still prompt conversions. The net effect is weakening customer bargaining power, tempered by active rival outreach.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTraining-driven lock-in\u003c\/li\u003e\n\u003cli\u003eCustomized sizing embeds supplier\u003c\/li\u003e\n\u003cli\u003ePreop workflow integration reduces churn\u003c\/li\u003e\n\u003cli\u003eCompetitor incentives can erode loyalty\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOutcome data and brand reputation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eClinical outcomes, safety profile and regulatory approvals (EVO ICL FDA approval 2022) drive buyer trust and reduce price sensitivity. Robust post‑market evidence shifts negotiations toward value rather than cost. Adverse events or recalls would rapidly raise customer bargaining power, while continuous evidence generation sustains STAAR’s pricing power.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFDA approval 2022\u003c\/li\u003e\n\u003cli\u003ePost‑market data = value leverage\u003c\/li\u003e\n\u003cli\u003eAdverse events → higher buyer power\u003c\/li\u003e\n\u003cli\u003eOngoing evidence sustains pricing\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSurgeons' leverage and \u003cstrong\u003e\u0026gt;1M\u003c\/strong\u003e ICLs reshape pricing, payments and value\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSurgeons and ASCs hold strong bargaining power due to clinical influence, volume purchasing and ability to demand training, pricing and inventory terms.\u003c\/p\u003e\n\u003cp\u003eDistributor tenders and GPOs compress prices and extend payment cycles (≈90 days), while patient cash-pay pricing ($4,000–$6,000\/eye in 2024) raises end‑user sensitivity.\u003c\/p\u003e\n\u003cp\u003eClinical outcomes, \u0026gt;1M ICLs implanted and FDA approval (EVO 2022) shift negotiations toward value, creating gradual lock‑in through training and workflow integration.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024 Value\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal ICLs implanted\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;1,000,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrice per eye (typical)\u003c\/td\u003e\n\u003ctd\u003e$4,000–$6,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTypical payment cycle\u003c\/td\u003e\n\u003ctd\u003e≈90 days\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eSTAAR Surgical Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis STAAR Surgical Porter's Five Forces analysis preview is the exact document you'll receive upon purchase—fully written, formatted and ready for immediate download. No placeholders or samples; the content shown is the final deliverable. Use it as-is for research, presentations or strategic decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":56163031941497,"sku":"staar-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/staar-five-forces-analysis.png?v=1762713243","url":"https:\/\/portersfiveforce.com\/products\/staar-five-forces-analysis","provider":"Porter's Five Forces","version":"1.0","type":"link"}